ROSEN, THE FIRST FILING FIRM, Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – PAYC
19 nov. 2023 13h20 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Paycom Software, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – PAYC
16 nov. 2023 13h55 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of...
Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study
21 sept. 2021 08h00 HE
|
Zenith Capital Corp.
CALGARY, Alberta, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”) and Newsoara BioPharma Co., Ltd. (“Newsoara”) announced today the initiation of a...
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
27 juin 2019 08h30 HE
|
Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
18 mars 2019 09h00 HE
|
Zenith Capital Corp.
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE...
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
20 nov. 2018 08h30 HE
|
Zenith Capital Corp.
Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...